Clinical trials: Multisystem Atrophy
Parkinson's Disease, Multiple System Atrophy
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
The gut may be a portal of entry for agents that cause or contribute to the causes of Parkinson's disease (PD). The investigators are studying changes in the normal population of gut flora and in intestinal permeability and their…
- Trial name
- NCT01155492
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Rush University Medical Center
Multiple System Atrophy
TRACK-MSA: A Longitudinal Study to Define Outcome Measures in Multiple System Atrophy
TRACK-MSA is an observational, non-interventional, longitudinal natural history study to define changes in clinical, neurological, blood, CSF, and neuroimaging biomarkers in patients with multiple system atrophy (MSA) comparing…
- Trial name
- NCT04450992
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- NYU Langone Health
Parkinson's Disease, Parkinsonism
VisMemoPD Protocol: an Observational Pilot Study on Spatial and Topographical Memory in Patients With Parkinson's Disease and Parkinsonism
VISMEMO-PD is an observational pilot study aimed at investigating visuospatial memory in reaching space and topographical memory in navigational space in patients with Parkinson's disease and Parkinsonism.
- Conditions
- Parkinson's Disease, Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- VISMEMO-PD (NCT07827963)
- Testing
- Multimodal visuospatial and topographical memory assessment
- Where
- 3 sites in Italy
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele Roma
Multiple System Atrophy
Therapeutic Education for Multiple System Atrophy (MSA) Patients and Their Caregivers
Multiple system atrophy (MSA) is a rare neurodegenerative disorder that leads to major disability, forcing patients and caregivers to adapt their environment and lifestyle.
- Trial name
- ETP@MS (NCT05819957)
- Testing
- Therapeutic Education Program (TEP)
- Where
- France
- Volunteers
- 15 people
- Sponsor
- University Hospital, Toulouse
Multiple System Atrophy
Efficacy and Safety of Bilateral Cervical Lymphatic-Venous Anastomosis in the Treatment of Multiple System Atrophy
Multiple System Atrophy (MSA) is a rare and aggressive neurodegenerative disorder characterized by a combination of motor impairments, autonomic dysfunction, and cerebellar ataxia, with no currently available disease-modifying…
- Trial name
- NCT07036939
- Testing
- Immediate LVA, Delayed LVA
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Ruijin Hospital
Multiple System Atrophy
A Study of TAK-341 in Treatment of Multiple System Atrophy
The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS).
- Trial name
- NCT05526391
- Testing
- TAK-341
- Where
- 41 sites in United States, Austria and 8 more
- Volunteers
- 158 people
- Sponsor
- Takeda
Dementia, Alzheimer Disease
The Swedish BioFINDER 2 Study
The Swedish BioFINDER 2 study is a new study that will launch in 2017 and extends the previous cohorts of BioFINDER 1 study (www.biofinder.se). BioFINDER 1 is used e.g.
- Conditions
- Dementia, Alzheimer Disease, Parkinson Disease, Lewy Body Disease
- Trial name
- BioFINDER2 (NCT03174938)
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948, Elecsys (Roche) Abeta42, Ttau and Ptau
- Where
- 2 sites in Sweden
- Volunteers
- 2,950 people, healthy volunteers welcome
- Sponsor
- Skane University Hospital
Multiple System Atrophy
A Prospective Exploratory Study of the Safety and Preliminary Efficacy of the α-Syn H21 Monoclonal Antibody in Patients With Multiple System Atrophy
Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, and cerebellar ataxia.
- Trial name
- NCT07774585
- Testing
- α-Syn H21 Monoclonal Antibody
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Ruijin Hospital
Parkinson Disease, Parkinsonism
More Than a Movement Disorder: Applying Palliative Care to Parkinson's Disease
This is a two-center (University of Colorado, University of California San Francisco) community-based comparative effectiveness study of outpatient palliative care for Parkinson's disease (PD) and related disorders (progressive…
- Conditions
- Parkinson Disease, Parkinsonism, Lewy Body Disease, Supranuclear Palsy, Progressive
- Trial name
- MTMD (NCT03076671)
- Testing
- Palliative Care
- Where
- 2 sites in United States
- Volunteers
- 783 people
- Sponsor
- University of Colorado, Denver
Autonomic Failure, Pure Autonomic Failure
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
The purpose of this study is to learn more about the effects of midodrine and droxidopa, two medications used for the treatment of orthostatic hypotension (low blood pressure on standing), on the veins of the abdomen of patients…
- Conditions
- Autonomic Failure, Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease
- Trial name
- NCT02897063
- Testing
- Droxidopa, Midodrine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Vanderbilt University Medical Center
Parkinson Disease, Multiple System Atrophy
Diagnostic and Prognostic Biomarkers in Parkinson Disease
The overall goal of PROBE is to evaluate the feasibility and potential utility of three markers (alpha-synuclein, transcriptomic profiles and olfactory function) to determine the risk or prognosis of PD.
- Conditions
- Parkinson Disease, Multiple System Atrophy, Progressive Supranuclear Palsy
- Trial name
- PROBE (NCT00653783)
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- The Parkinson Study Group
Parkinson's Disease, Multiple System Atrophy
Clinical Laboratory Evaluation of Chronic Autonomic Failure
Background: The autonomic nervous system controls automatic body functions. Researchers want to improve the tests used to diagnose autonomic failure. Orthostatic hypertension is a drop in blood pressure when a person stands up.
- Conditions
- Parkinson's Disease, Multiple System Atrophy, Autonomic Failure
- Trial name
- NCT03648905
- Testing
- 13N-Ammonia, 18F-DOPA, 11C-Methylreboxetine (11C-MRB)
- Where
- United States
- Volunteers
- 89 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic
Feasibility Study Assessing the Effect of Carbidopa/Levodopa Ratio on Orthostatic Hypotension in Multiple System Atrophy - Parkinsonian Type and Parkinson Disease.
This study is aimed at patients with multi-system atrophy - parkinsonian type (P-MSA) or Parkinson's disease (PD) receiving dopaminergic drugs and suffering from orthostatic hypotension (OH).
- Conditions
- Multi-system Atrophy - Parkinsonian Type, Orthostatic Hypotension, Dysautonomic, Parkinson Disease
- Trial name
- CARBIDOH (NCT06831500)
- Testing
- Administration of Carbidopa/levodopa
- Where
- 2 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Julien Bally
Transcranial Magnetic Stimulation, Multiple System Atrophy
TMS Treatment in Multiple System Atrophy With Fatigue
Transcranial magnetic stimulation (TMS) is a procedure that has been shown to improve fatigue in chronic sufferers. It uses a plastic covered coil that sends a magnetic pulse through the skull into the brain and by targeting…
- Conditions
- Transcranial Magnetic Stimulation, Multiple System Atrophy, Fatigue
- Trial name
- TMSMSAF (NCT04313530)
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Xuanwu Hospital, Beijing
Multiple System Atrophy - Cerebellar Subtype (MSA-C), Multiple System Atrophy - Parkinsonian Subtype (MSA-P)
TSPO PET in the Evaluation of Neuroinflammation in Patients with Multiple System Atrophy
The aim of this study was to apply PET/MR techniques targeting TSPO to explore the temporal and spatial alterations characterizing neuroinflammation in MSA patients, and to assess its value as a biomarker for diagnostic typing…
- Trial name
- NCT06890390
- Where
- China
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Min Zhao,MD
Frontotemporal Degeneration, Progressive Supranuclear Palsy
Cognitive Impairement In Frontotemporal Dementia
This is an observational study that aims to better understand the genetic causes of frontotemporal degeneration (FTD), Multiple Systems Atrophy (MSA), and Progressive Supranuclear Palsy (PSP).
- Conditions
- Frontotemporal Degeneration, Progressive Supranuclear Palsy, Multiple System Atrophy
- Trial name
- NCT03452956
- Testing
- None-Observation Only
- Where
- United States
- Volunteers
- 997 people
- Sponsor
- University of Pennsylvania
Multiple System Atrophy, Orthostatic Hypotension
Reduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic
The purpose of this study is to learn more about the regulation of the veins of the abdomen by the autonomic (involuntary) nervous system, and how this may affect high blood pressure.
- Conditions
- Multiple System Atrophy, Orthostatic Hypotension, Supine Hypertension
- Trial name
- NCT02726711
- Testing
- Trimethaphan
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt University
Multiple System Atrophy (MSA)
Oligomeric Alpha-synuclein in Multiple System Atrophy
The main objectives are to determine on one hand whether oligomeric alpha-synuclein levels are increased in MSA patients compared to controls and on other hand whether there is a good agreement between cerebrospinal fluid (CSF)…
- Trial name
- BIOAMS (NCT01485549)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- University Hospital, Bordeaux
Ataxia, Cerebellar, Multiple System Atrophy
Tllsh2910 for Ataxia and Gut Microbiota Alteration in Patients of Multiple System Atrophy
Multiple system atrophy (MSA) is a fetal, rare neurodegenerative disease presenting with parksinonism, autonomic dysfunction, and cerebellar ataxia. Numerous anti-parkinsonism agents have been developed.
- Trial name
- NCT03901638
- Testing
- Tllsh2910
- Where
- Taiwan
- Volunteers
- 18 people
- Sponsor
- National Taiwan University Hospital
Multiple System Atrophy
Observational Study in Multiple System Atrophy
Talisman is global clinical study (20058N) in Multiple System Atrophy (MSA) patients. It will be conducted in two regions (China and the European Union [EU]).
- Trial name
- TALISMAN (NCT05453058)
- Testing
- plasma NfL and brain MRI (vMRI, DTI, and ASL [if feasible]) only for the EU cohort
- Where
- 8 sites in China
- Volunteers
- 90 people
- Sponsor
- H. Lundbeck A/S